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Objective: Prospective analyses of quality of life in elderly patients after lobectomy
are limited, yet surgeons often recommend suboptimal therapy to these patients on
the basis of the belief that lobectomy is poorly tolerated. Surgical decision making
in elderly patients with lung cancer is better informed when the benefits to survival
and quality of life after lobectomy are understood.
Methods: By using a validated quality of life instrument, 422 patients were prospec-
tively assessed preoperatively and 3, 6, and 12 months after lobectomy. Outcomes
were analyzed with respect to age (group 1: ,70 years and group 2: $70 years).
The outcome domains of physical functioning, role functioning, emotional function-
ing, cognitive functioning, social functioning, global health, and pain in the chest were
analyzed using a mixed model. The trend in quality of life was determined according
to age. The Kaplan–Meier method was used for analysis of overall survival.
Results: The mean age was 60.1 years in group 1 (N5 256) and 74.7 years in group 2
(N5 166). Baseline demographics and quality of life were similar except that group 2
had better emotional functioning scores and worse pain in the chest scores. Postoper-
atively, both groups demonstrated significant decreases in quality of life at 3 months.
However, at 6 and 12 months, all domains had returned to baseline except physical
functioning, which remained below baseline in group 2. Emotional functioning im-
proved postoperatively for both groups. Overall survival at 5 years was not different
between groups.
Conclusion: By using a validated quality of life assessment tool with measurements at
baseline and serially after resection in a large patient population, this analysis quan-
tifies the degree of impairment of quality of life after lobectomy and documents
time to full recovery for both age groups.
I
n patients with early-stage non–small cell lung cancer (NSCLC), lobectomy
achieves the best long-term survival.1 Yet, successful operations for stages I
and II lung cancer are associated with a 5-year survival of only 40% to 70%.2
Thus, treatment is often palliative rather than curative. Most studies published to
date are concerned primarily with traditional outcomes, such as operative morbidity
and mortality or long-term survival. The complex interplay among the treatment’s
benefits, risks, and the expectations held by patients with lung cancer serve to focus
attention on the importance of health-related quality of life (QOL).
Information on QOL after operations for lung cancer surgery is sparse. Between
1994 and 2004, only 9 published articles were found that described QOL after lung
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cancer operations.3-11 Of the 9 studies, only 3 included pre-
operative assessments, and although most used a validated
QOL instrument, only 2 used a cancer-specific instru-
ment.8,10 Clearly, a prospective, longitudinal study that
follows a large patient population and that uses a cancer-
specific instrument is needed to more accurately portray
QOL after lung cancer operations.
Lung cancer disproportionately affects the elderly, with
a median age at diagnosis of 70 years.12 Prospective analyses
of QOL in elderly patients after lobectomy are absent, yet sur-
geons may recommend operations with less proven onco-
logic efficacy to these patients on the basis of the belief
that lobectomy is poorly tolerated. Surgical decision making
in elderly patients with lung cancer is better informed when
the benefits of lobectomy to survival and QOL are under-
stood.
Materials and Methods
This is a retrospective review of prospectively collected data. The
study was approved by the institutional review board at Duke
University Medical Center.
Patients and Quality of Life Assessments
Patients with suspected lung cancer, who were seen in the Duke
Thoracic Oncology Program, were asked to complete a QOL ques-
tionnaire preoperatively and then postoperatively at 3, 6, and 12
months. A trained clinical research assistant administered the ques-
tionnaire on a touch-screen computer, and attempts weremade to ad-
minister the questionnaire before meeting with the clinician. Only
patients who completed the baseline QOL assessment and at least
1 postoperative QOL assessment, and had undergone an anatomic
lobectomy were included in the study. For purposes of analysis,
patients in group 1 were defined as less than 70 years of age and
patients in group 2 were defined as 70 years or older.
Quality of Life Measures
QOL was assessed using the European Organization for Research
and Treatment of Cancer Quality of Life Questionnaire (EORTC-
QLQ-C30). The QLQ-C30 is a validated instrument for measuring
QOL in patients with cancer and consists of 5 functional scales, 3
symptom scales, and a global health status/QOL scale (sample
questions can be seen at http://groups.eortc.be/qol/downloads/
modules/specimen_20qlq_c30.pdf).13 In addition, 2 symptom
scales for pain in the chest and pain in the arm/shoulder, as well
as a dyspnea symptom scale, from the validated lung cancer mod-
ule (QLQ-LC13), were used. Both questionnaires are designed for
self-completion by the patient. For the functional scales (ie, those598 The Journal of Thoracic and Cardiovascular Surgery c Sepexploring physical, role, emotional, cognitive, and social function-
ing) and global health status, a higher value corresponds to a higher
level of function or high QOL. Conversely, a higher score in
a symptom scale corresponds to a higher level of symptoms or
problems.
Statistical Considerations
The baseline characteristics of group 1 and group 2 were compared
using the Fisher’s exact test for dichotomous outcomes, and a 2-
tailed t test was used for continuous variables. QOL scores col-
lected from the EORTC QLC-C30 were linearly transformed to
a scale of 0 to 100 in accordance with the EORTC guidelines.14
The major objective of this study was to determine how QOL
changed longitudinally and to compare differences between group
1 and group 2. This comparison was made by fitting a linear mixed
model for repeated measures with restricted maximum likelihood
estimation method for each EORTC functional scale, the global
QOL scale, as well as 2 pain scales and the dyspnea scale (SAS
PROC MIXED, SAS Institute Inc, Cary, NC). Effects modeled in-
cluded the patient’s age group, survey time (preoperatively, 3, 6, or
12 months), and interaction between age group and survey time. Of
primary interest in these analyses was the interaction, a measure of
whether the effect of time on outcomes was the same between the 2
groups.
Because 20% to 38% of data were missing, sensitivity analyses
were conducted to examine the effect of missing data on inferences.
The model was reanalyzed with data imputed to replace the missing
data. A Monte Carlo Markov Chain approach to multiple imputa-
tions was used with SAS PROCMI. The correlation of the 4 assess-
ments of each outcome, marital status, living situation, sex, stage,
education, and video-assisted thoracic surgery use, were used in es-
timating 5 complete datasets or imputations. A mixed linear model
TABLE 1. Baseline demographics
Group 1 (N 5 256) Group 2 (N 5 166)
Mean age, y (range) 60.1 (33–69) 74.8 (70–93)
Male (%) 44.1 52.4
Married (%) 69.1 63.9
Schooling (%)
High school or less 56.2 56.6
Attended college 35.9 35.5
Graduate degree 7.8 7.8
Race (%)
White 82.8 91.6
African American 14.4 8.4
Other 2.3 0
Diagnosis (%)
NSCLC 91.0 94.5
Squamous 30.5 36.7
Adenocarcinoma 60.5 57.8
Stage 1 or 2 86.4 86.7
Surgery technique (%)
Thoracoscopic 59.0 67.5
Thoracotomy 41.0 32.5
NSCLC, Non–small cell lung cancer.tember 2008
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the effect of time, age group, and their interaction. The results for the
interaction were combined across models using SAS PROC MIA-
NALYZE.
The survival function was estimated using the Kaplan–Meier
method. Overall survival was calculated from the date of surgery
to the date of death from any cause or censored at June 1, 2006. Sur-
vival was expressed as a proportion, and survival curves were com-
pared using the log-rank statistic. SAS version 9.1 (SAS Institute
Inc) was used for all analyses.
Results
Patients
Between January 1, 1999, and September 25, 2005, 564 pa-
tients took an initial QOL survey and underwent lobectomy
at Duke University Medical Center. A total of 142 patients
(N 5 82 group 1 and N 5 60 group 2) took only 1 survey
and were excluded from this analysis. Reasons for patients
taking only 1 survey included death within 3 months of
surgery (N 5 8 group 1 and N 5 12 group 2, P 5 .09), pa-
tients still within first 3 months of follow-up (N 5 16 group
1 and N 5 6 group 2, P 5 .16), and patients who were still
alive but lost to follow-up (N5 58 group 1 and N5 42 group
2, P 5 1.0).
TABLE 2. Baseline quality of life, mean scores
Group 1 Group 2 P value
Physical functioning 83.7 81.0 .2
Role functioning 82.2 82.4 .9
Emotional functioning 74.1 78.9 .02
Cognitive functioning 85.0 85.8 .6
Social functioning 85.8 86.7 .6
Global QOL 69.9 68.7 .6
Pain in chest 16.2 8.0 ,.0001
Pain in arm/shoulder 18.8 16.8 .4
Dyspnea 27.1 25.0 .5
QOL, Quality of life.The Journal of ThoA total of 422 patients completed at least 1 postoperative
survey and were included in this study. Demographics from
the eligible patients are listed in Table 1. As indicated, the
majority of patients were white and married, and had stage
1 or 2 NSCLC. The 2 groups were well balanced with respect
to patient characteristics.
Quality of Life at Baseline
In compliance with entry criteria, all patients had preopera-
tive QOL assessments. Table 2 summarizes the baseline
QOL for each functional scale and symptom scale. The 2
groups were similar except that group 2 had higher emotional
functioning and less pain in the chest at baseline.
Quality of Life Completion
All patients were asked to complete the QOL questionnaire at
regularly scheduled follow-up appointments starting 3
months postoperatively. Subsequent completion rates varied
between 62% and 80% for both groups (Table 3). Completion
rates for each survey time point were similar between groups
except at the 3-month survey, where 72% of group 1 and 62%
of group 2 completed surveys (P 5 .39). The most common
reason for not completing a survey was failure to show in
the clinic. Because of the retrospective nature of the study, it
was impossible to capture the patient’s specific reason for fail-
ing to show in the clinic at the proper survey time (eg, too sick,
feeling too well, receiving cancer follow-up elsewhere).
Longitudinal Quality of Life
Subsequent QOL mean scores are listed in Table 4. Both
groups 1 and 2 experienced significant reductions in physical
functioning, role functioning, social functioning, and global
QOL domains at the 3-month survey. Similarly, both groups
had increased pain in their chests and arm, aswell as increased
dyspnea, at 3 months. By the 6-month survey, the QOL do-
mains had returned to baseline for both groups. All domains
except physical functioning remained not significantly differ-
ent from baseline at the 12-month survey (Figure 1). PhysicalTABLE 3. Quality of Life Questionnaire compliance
Group 1 Group 2
Survey Time (mo) Survey Time (mo)
Preop 3 6 12 Preop 3 6 12
No. No. % No . % No. % No. No. % No . % No. %
Assessments expected 256 256 254 247 166 166 164 156
Patient deaths 0 0 2 7 0 0 2 8
Assessments performed 256 184 72 203 80 178 72 166 103 62 132 80 112 72
Reason missed
Did not come to clinic 72 28 46 18 62 25 60 36 27 17 33 21
Refused 0 1 0.4 2 0.8 0 0 3 2.0
Institutional error 0 4 1.6 5 2.0 3 1.8 5 3.0 8 5.1racic and Cardiovascular Surgery c Volume 136, Number 3 599
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Group 1 Group 2
Assessment point Mean score SD Mean score SD
Preoperative survey
Physical functioning 83.7 19.3 81.0 20.8
Role functioning 82.2 27.3 82.4 27.9
Emotional 74.1 21.5 78.9 19.6
Functioning 85.0 19.6 85.8 17.8
Cognitive 85.8 22.3 86.7 22.3
Functioning 69.9 21.5 68.9 24.2
Social functioning 16.2 25.1 8.0 17.6
Global QOL 18.3 22.8 16.8 25.7
Pain in chest 27.1 26.8 25.0 29.3
Pain in arm
Dyspnea
3-mo survey
Physical functioning 77.9 18.4 73.9 24.6
Role functioning 65.3 30.1 63.9 32.5
Emotional 74.2 22.8 77.2 20.6
Functioning 81.4 21.3 84.8 18.0
Cognitive 76.8 25.9 77.2 28.2
Functioning 63.5 22.3 62.1 22.1
Social functioning 26.6 26.9 18.4 23.8
Global QOL 33.4 28.7 26.1 25.7
Pain in chest 41.7 27.6 40.5 30.5
Pain in arm
Dyspnea
6-mo survey
Physical functioning 79.4 20.2 79.4 20.7
Role functioning 73.7 29.9 78.2 28.0
Emotional 76.6 20.2 82.4 18.0
Functioning 82.0 19.9 85.8 18.9
Cognitive 81.4 26.3 86.2 22.3
Functioning 68.3 21.9 69.7 20.9
Social functioning 18.4 24.5 10.9 19.0
Global QOL 23.8 25.7 23.2 26.4
Pain in chest 38.1 26.5 37.7 30.4
Pain in arm
Dyspnea
12-mo survey
Physical functioning 81.9 19.1 78.0 22.8
Role functioning 79.0 27.0 80.4 29.0
Emotional 78.5 21.1 82.4 18.5
Functioning 83.4 19.8 83.6 18.9
Cognitive 82.6 24.4 87.8 23.2
Functioning 70.5 23.3 69.8 21.6
Social functioning 16.7 23.1 9.7 17.0
Global QOL 22.2 25.3 17.6 22.9
Pain in chest 33.0 25.7 32.7 30.8
Pain in arm
Dyspnea
SD, Standard deviation; QOL, quality of life.600 The Journal of Thoracic and Cardiovascular Surgery c Sepfunctioning decreased below baseline in group 2 at the 12-
month survey. Emotional functioning did not change at the
3-month survey but then significantly increased at both the
6 and 12-month surveys for both groups. Cognitive function-
ing did not differ from baseline at any of the subsequent
survey times. The symptom scales for pain returned to preop-
erative values by 6months and remained similar to baseline at
12 months. The dyspnea symptom scale recovered some but
remained above baseline for the 6 and 12-month surveys.
The linear mixedmodel examining the overall effect of the in-
teraction between survey time and group was not significant
for any domain or symptom scale. This suggests that although
both groups experienced changes in QOL over the year, they
did not differ from each other. The P values for the overall in-
teraction were as follows: physical functioning 5 .08, role
functioning 5 .33, emotional functioning 5 .20, cognitive
functioning 5 .24, social functioning 5 .08, global QOL 5
.54, pain in chest 5 .98, pain in arm 5 .39, and dyspnea 5
.89. The sensitivity analysis with multiply imputed data
sets confirmed that there was no evidence of a statistically
significant interaction. The resulting P values were physical
functioning 5 .36, role functioning 5 .65, emotional
functioning 5 .40, cognitive functioning 5 .35, social func-
tioning5 .38, and global QOL 5 .85.
Survival
Survival for the 2 groups is depicted in Figure 2. Median
follow-up for the whole cohort was 28.3 months. Median
survival was calculated to be 73.1 months for group 1 and
56.7 months for group 2. There was no significant difference
between survival curves by log-rank test (P 5 .72).
Discussion
Health-related QOL is being increasingly recognized as an
important issue in cancer care and research. Yet, information
on QOL after lung cancer operations is limited. This study
compared preoperative and postoperative QOL after lobec-
tomy in 422 patients and specifically analyzed these changes
with respect to age. A clinically validated, cancer-specific in-
strument was used to measure QOL in patients who under-
went lobectomy predominantly for early-stage NSCLC. To
our knowledge, this study represents the largest prospective,
longitudinal, evaluation of QOL in patients undergoing oper-
ations for lung cancer to date.
The multidimensional nature of the QOL assessment rai-
ses some important issues of interpretation. Multiplicity of
comparisons and interdependency of responses at successive
times make it necessary to focus on the whole pattern of re-
sults. The exclusive use of patients with complete data pro-
vides unbiased, albeit inefficient, results, if the data that are
missing occurs completely at random. Alternatively, it pro-
vides biased results, if data that are missing occurs not com-
pletely at random (the more common form of missingness).
In this study we used a linear mixed-effect model to analyzetember 2008
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Figure 1. QOL after lobectomy. Mean
QOL domain scores plotted as a function
of survey time.all available data and to reconcile the fact that intrasubject
QOL measurements are not independent (repeated mea-
sures).15 On the basis of this analysis, both groups demon-
strated significant reductions in physical, role, social, and
global QOL domains, as well as increased pain involving
the chest and arm/shoulder, and increased dyspnea at 3
months postoperatively. All parameters, except dyspnea,
had recovered to baseline values by 6 months. Both groups
demonstrated a similar decrement in QOL with a parallel re-
turn to baseline. The one notable exception was in the domain
of physical functioning, which had returned to baseline by 6
months and decreased below its preoperative value in pa-
Figure 2. Overall survival via the Kaplan–Meier method. Survival
was compared with the log-rank statistic.The Journal of Thotients 70 years or older by 12 months. It is unclear whether
physical functioning remained reset at this lower level or con-
tinued to deteriorate over time in these patients.
Patients aged 70 years or more had less impairment in
emotional functioning preoperatively. This domain remained
at its baseline value in both groups through the first 3 months
after operation, but then demonstrated a significant increase
by 6 months. This trend persisted through the end of the
study. This reduction in emotional functioning preopera-
tively may be explained in part by the psychologic impact
related to the recent cancer diagnosis. Not surprisingly, wors-
ened emotional functioning seems to affect younger patients
more than the older patients. In a similar pattern, older
patients seem to perceive pain as being less severe both at
baseline and postoperatively when compared with younger
patients.
The observation that QOL decreases over the first 3 to 6
months postoperatively and then returns to its preoperative
level has been reported by others. Dales and colleagues9 re-
ported on 117 patients who underwent thoracotomy for pre-
sumed lung cancer (NSCLC in 91, other pathology in 26).
QOL was measured with the Sickness Impact Profile (SIP)
and Spitzer QL-Index preoperatively and at 1, 3, 6, and 9
months postoperatively. Dales and colleagues found that
QOL and dyspnea significantly worsened at 1 and 3 months
postoperatively but returned to baseline at 6 and 9 months.
Zieren and colleagues10 reported similar findings using the
Spitzer QL-Index and an earlier version of the EORTC
QLQ (QLQ-CLC36). They examined 2 cohorts of patients
who had undergone curative operations for lung cancer; 1 co-
hort completed a single QOL survey 12 months postopera-
tively (N 5 52) and another was surveyed preoperatively
and then again at discharge (median 11 days) and 3, 6, 9,
and 12 months postoperatively (N5 20). In the latter cohort,racic and Cardiovascular Surgery c Volume 136, Number 3 601
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and global domains of QOL, and increases in disease symp-
toms, such as dyspnea, at discharge. These differences, how-
ever, had disappeared at the 3-month survey.
Handy and colleagues6 reported on 139 patients undergo-
ing lung resections who were evaluated with the short-form
health survey [36 items] and the Powers’ QOL index before
operation and then again at 6 months after operation. Preoper-
ative QOL in patients undergoing operation for lung cancer
was significantly worse than in healthy controls. Handy and
colleagues found that at 6months, subscales for physical func-
tioning, role-physical, bodily pain, and mental health on the
short-form health survey [36 items] were significantly worse
than baseline. Because the data collected were truncated at 6
months, however, it is uncertain whether these findings per-
sisted at 12 months. In addition, Handy and colleagues found
that emotional functioning, although not significantly wors-
ened, failed to improve with time. An unanswered question
iswhether the difference in their findings comparedwith those
of the present study can be attributed to a different patient pop-
ulation or differences in QOL instruments.
Compliancewith theQOL assessment, defined as the num-
ber of assessments actually completed as a proportion of those
expected, ranged from 62% to 80%.16 The most commonly
missed survey time point was the 3-month survey with 28%
of group 1 and 38% of group 2 missing this time point. Miss-
ing data were rarely the result of patient refusal or neglect, be-
cause a trained clinical research nurse guided each patient
through their surveys. A more common reason was a failure
of the patient to return for clinic follow-up within the pre-
scribed time frame. Compliance with the QOL assessment
is important because the failure to return for clinic follow-
up may be influenced by the patient’s QOL at that particular
time point.17 Because of the retrospective nature of this study,
it is not possible to determine whether a patient missed the as-
sessment because of postoperative disability, with associated
poor QOL, or because he or she was recovering exceptionally
well and chose to skip a clinic visit. Moreover, because of our
large referral area, some patients may have chosen to receive
part of their cancer care with their local area physician. Cer-
tainly, the larger percentage of group 2 patients who missed
their 3-month survey could introduce significant bias if these
patients did so because of increased postoperative disability.
Missing data are common in QOL studies, and they are
usually not missing completely at random.18 Thus, to account
for missing data, appropriate statistical modeling (linear
mixed model) was used. Sensitivity analysis was performed
by replacing the missing data with multiply imputed values
that were generated from individual baseline characteristics
and previous QOL values.19 Furthermore, the same linear
mixed model was used to analyze each of the 5 imputed data-
sets, and SAS PROC MIANALYZE was applied to combine
the results across models. Although it is impossible for any
model to completely remove all possible bias, the findings602 The Journal of Thoracic and Cardiovascular Surgery c Sepfrom this analysis confirmed the original results; no difference
in QOL was observed between groups.
Overall survival for the 2 groups was not different,
whereas median survival time for the 2 groups appeared dif-
ferent because of a separation in survival curves at approxi-
mately 60 months. The median survival was 73 months for
group 1 and 56.7 months for group 2.
The most important limitation to the generalizability of
this study’s findings is the selection bias inherent in its retro-
spective design. The study cohort represented patients who
were motivated and willing to complete QOL surveys, preop-
eratively and postoperatively. This study delineated the time
course of change in QOL after lobectomy, but its conclusions
obviously do not help a surgeon choose which particular
elderly patient will survive a major lung cancer operation. In-
deed, although not statistically significant, more patients in
group 2 died within 90 days of completing the preoperative
survey than in group 1 (12 patients in group 2 vs 8 patients
in group 1). Another limitation to this study’s generalizability
is the relatively high percentage of women who were enrolled
(55.9% in group 1 and 47.6% in group 2). This proportion is
slightly higher than the general pool of patients with lung
cancer and may indicate that women generally are more will-
ing to complete QOL surveys.
To summarize the main findings, this study delineates the
magnitude of the change in QOL experienced by younger and
older patients undergoing anatomic lobectomy and shows
that they have similar decrements to 3 months. This study
also documents that the time course to recovery of QOL in
both groups is generally less than 6 months.
Conclusions
This study examined the longitudinal QOL in a large cohort
of patients with lung cancer undergoing lobectomy, using
a clinically validated, cancer-specific instrument. Postopera-
tive QOL was reduced transiently and to a similar degree in
patients aged less than 70 years and in patients aged 70 years
or more. Further, the 5-year survival between groups was
equivalent. These data support the use of lobectomy in
selected elderly patients with lung cancer.
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Discussion
Dr Francis C. Nichols (Rochester, Minnesota). Dr Burfeind and
colleagues have pointed out that surgical morbidity, mortality, and
long-term survival have been our traditional reported outcome pa-
rameters. However, with multimodality diagnostic and treatment
options now becoming routine in patients with certain diseases, par-
ticularly lung cancer, an ever-increasing amount of time has to be
spent by patients in investigating, treating, and hopefully regaining
their personal health. This has resulted in a growing appreciation
about health-related QOL for these patients. Specifically regarding
our patients with lung cancer, who are indeed oftentimes middle-
age, as you said, or older, it would seem that knowledge of QOL
would provide useful information, in fact, essential information
for the patients, their families, primary care providers, and other spe-
cialists, namely, our referrers. In broad terms, QOL is a concept that
is easy to intuitively grasp but difficult to reliably measure. It’s a dy-
namic concept varying over time. The authors are to be commended
on the prospective nature of this study dating back to 1999, which
involved a large cohort of patients, 422, which to my knowledge
represents the largest number of patients thus reported on. As a cli-
nician, I worry about missing data. Although many of us in the roomThe Journal of Thoaren’t statisticians, I and perhaps others get nervous when 20% to
38% of the data are missing. I would have thought that with a dedi-
cated clinical research assistant administering the questionnaire and
use of a computer that missing data elements could have been less or
caught earlier. If the missing data were due to patients not keeping
their scheduled clinic appointments, is there any process now in
place for avoiding that in the future? Could you please comment
on this 20% to 38% missing data and the validity of imputing data?
Dr Burfeind. As you know, missing data is a common problem
in QOL research, and it’s important because the reason it’s missing
can often be related to a patient’s QOL. That being said, if they don’t
come to the clinic, there are numerous reasons why that may happen.
It may be that their QOL is so poor that they don’t come to the clinic.
Alternatively, in some instances it could be that they’re feeling so
well that they skip a clinic appointment or that they receive part
of their care elsewhere, and at a large referral center, such as
Mayo or Duke, many people will get referrals from elsewhere and
some of the patient’s postoperative care may be assumed closer to
home. I think those are some of the reasons explaining the missing
data. As you may have noticed, it was almost never missing because
of a patient coming to the clinic and then either refusing to take the
survey or us just forgetting to administer it. It was almost always be-
cause the patient didn’t show up in the clinic. As far as the imputa-
tion method, I think we used the most up-to-date method to do that;
that is, it took into effect the patient’s other QOL scores as well as
the preoperative variables that I had said earlier. So we tried to
use all available data to impute rather than either throwing out all
the patients who didn’t have complete data or using the last value
forward or mean value methods. Although no method of imputation
is perfect, we tried to use a method that would introduce the least
amount of bias.
Dr Nichols. My second question relates to the respondents. As
you said, the majority of the respondents were women and 82%
of the respondents were both white and married. Initially, 564 pa-
tients were given the survey and underwent lobectomy. Do you
have any idea howmany patients never participated in the initial sur-
vey process and still underwent lobectomy at Duke, and would their
demographics have altered the characteristics of your cohort?
Dr Burfeind. It’s possible, and that’s certainly a bias. We do not
collect the information prospectively on who decides to participate
and who doesn’t. I do know that we perform approximately 300 an-
atomic lobectomies per year, so that would be approximately one
third of the patients are participating in this study.
Dr Nichols. My final question relates to your conclusion that
QOL domains after lobectomy are similar and usually transient in
these 2 groups, and because the 5-year survival data between the
groups is no different, your data therefore support lobectomy in
the elderly. What I don’t think has been addressed is the clinical de-
cision-making process that qualified these patients for lobectomy in
the first place. I think I, my colleagues, and others here in this room,
with a reasonable degree of comfort, can predict who we can get
through operations and ultimately out of the hospital. What I haven’t
mastered is which patients will have their QOL devastated. Was
there a difference between the 2 groups in terms of operative mortal-
ity, or, for that matter, morbidity, and did this have any relationship
with your preoperative QOL scores?
Dr Burfeind. That’s a very good point, and I think that’s the
most important limitation to this study. This is taking that groupracic and Cardiovascular Surgery c Volume 136, Number 3 603
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through a lobectomy, and, in fact, did get through the lobectomy.
Because you had to take a preoperative and at least 1 postoperative
QOL assessment, that means you survived at least 90 days. I think
what it does say, though, is that in that group of patients who you
think you can get through the operation, their QOL isn’t usually
devastated, on average, or as it would be measured here, but in
fact they will have a transient decrease, but it should come back
to baseline. The more important question that you had was can
we do something to help predict which patients are going to sur-
vive, and I am actually looking at that information now and trying
to see whether baseline QOL can predict 30-day mortality. It has
been shown in some other types of cancer and it may here. It’s
just that I need some more time to make sure it’s not confounded
by things like performance status and forced expiratory volume in
1 second and make sure that it shakes out in a multivariable model
that way.
Dr Nichols. You and your colleagues are to be commended on
trying to move us forward in our quest of furthering our understand-
ing of QOL.
Dr Scott J. Swanson (New York, New York). Obviously I’m go-
ing to ask you one question. Did you look at video-assisted thoracic
surgery as a separate category and did that have any effect? If we’re
going to do one at a time, I’ll have one other question.
Dr Burfeind. Being from Duke, I definitely looked at that. This
dataset was not ideally set up to answer that question. The short an-
swer is there was no difference between QOL in those 2 groups. I
think the main problemwas that by using 3months as your first post-
operative QOL time point, you’re missing the boat. The main advan-
tages to video-assisted thoracic surgery lobectomy may have been
most significant at 1, 2, or 6 weeks, even 2 months. The 3-month
time point was the one that had the most missing data. So it makes
it really hard to draw firm conclusions.
Dr Swanson. The second question, 70 years of age is getting to
be sort of younger for us as we go on here. Did you look at sort of
extreme ages, maybe more than 80 or 85 years, and see if that was
different?
Dr Burfeind. I didn’t, and I think that’s a great point, Scott. I
picked 70 years because it was the median age of patients diagnosed
with lung cancer in the United States. Most previous studies had
used a cutoff of 65 years to describe elderly patients. We’re glad
when somebody is 65 years. That’s one of the young patients. But
I also didn’t keep age as a continuous variable and try to find
some cut point above which QOL seemed to suffer more. I could
go back and do that, but it makes the statistical model quite complex.
So actually I don’t have the answer.
Dr Swanson. Do you know how many patients aged more than
80 years are in that group?604 The Journal of Thoracic and Cardiovascular Surgery c SepDr Burfeind. Seventeen of the 166 patients were 80 years or
older, so the majority of patients in group 2 were between 70 and
80 years.
Dr Michael T. Jaklitsch (Boston, Massachusetts). Thank you
for this study. I think it’s a very important contribution. If for no
other reason, suggesting that whatever nadir there is that may
have separated the 2 groups is resolved by 3 months, that in and
of itself is extremely valuable data. There are 2 other variables
that I would ask you to look at within this dataset. What was the in-
cidence of people going to rehabilitation facilities? In particular, that
3-month mark may be that they have gotten out of rehabilitation and
they’re not quite strong enough to make the trip back down to Dur-
ham. So that becomes an important variable. And then also, because
respiratory reserve declines as a function of age, if you look at which
lobe was taken, you may pick up a signal there on the lower lobes,
because if you take a lower lobe in an 80-year-old patient, that’s
a much bigger hit than if you took the upper lobe.
Dr Burfeind. I agree. I will look at those things. The retrospec-
tive nature of this made it difficult to try and parse out why some-
body didn’t come back to the clinic. You know, if this had been
in a randomized trial and we were very closely monitoring that,
we probably would have called to find out why they didn’t come
back, and that is a very important limitation and a source of impor-
tant bias in this study.
DrThomasW.Rice (Cleveland, Ohio).Age is a continuous var-
iable, and by dichotomizing your data, you’ve lost a lot. So you
would do us a big service by looking at the continuum and telling
us if there is a certain age we should be worried about. And most
of us aren’t concerned about the 70-year-old. We’re concerned
about the 80-year-old. So please do it as a continuous variable.
Dr Burfeind. Thank you, Dr Rice.
Dr Neri M. Cohen (Baltimore, Maryland).What number of pa-
tients go on to get adjuvant therapy? Because that nadir in the 3
months is when the 1B’s and the II’s are going to be in the midst
of their chemotherapy, and I can’t tell you how many times they
come back and tell me at 3 months, ‘‘The surgery was a breeze.
The chemo is killing me.’’
Dr Burfeind. That’s a very good point, and I didn’t look at that.
Dr Douglas E. Wood (Seattle, Washington). I’ll make one other
point about your conclusions. I guess I’ll be even more optimistic
than some of the other discussants and say that your conclusions
said that one can consider resection in selected elderly patients. I
guess I would be even more bold just to say that the default position
would be that we would consider resection in all elderly patients and
that one has to have a compelling reason not to offer it rather than the
other way around.
Dr Burfeind. Thank you, and I think that is the approach we typ-
ically take, exactly.tember 2008
